I say around $1 on the negative P3 outcome, above 9 (maybe even low double digits) of positive news.
Ppl do not forget that this is not just about soft tissue sarcoma. If this Ph3 sarcoma study proves Pali's superiority, it opens a clear path for the small-cell lung cancer Ph3 study that is already in the works (the same setting in which IFOS in the past proved efficacy but was too toxic for approval). SCLC market is many multiples of the sarcoma's commercial potential. Do not think I'm crazy, but ZIOP (if not bought out) can be a $100 stock within 2-3 years.